ASX - By Stock
|
KZA |
Re:
Ann: Executive Leadership changes - Dr John Friend appointed CEO
|
|
Gofish1
|
55 |
18K |
7 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
55
|
18K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Executive Leadership changes - Dr John Friend appointed CEO
|
|
Gofish1
|
55 |
18K |
4 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
55
|
18K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Executive Leadership changes - Dr John Friend appointed CEO
|
|
Gofish1
|
55 |
18K |
2 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
55
|
18K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia presents new data at AACR Annual Meeting
|
|
Gofish1
|
36 |
14K |
8 |
19/04/23 |
19/04/23 |
ASX - By Stock
|
36
|
14K
|
8
|
|
ASX - By Stock
|
KZA |
AACR 2023 April 14-19
|
|
Gofish1
|
5 |
2.2K |
11 |
30/03/23 |
30/03/23 |
ASX - By Stock
|
5
|
2.2K
|
11
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia raises $4.5m and launches share purchase plan
|
|
Gofish1
|
32 |
11K |
5 |
16/01/23 |
16/01/23 |
ASX - By Stock
|
32
|
11K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
4th GBM CONFERENCE MARCH NEXT
|
|
Gofish1
|
7 |
2.9K |
11 |
15/01/23 |
15/01/23 |
ASX - By Stock
|
7
|
2.9K
|
11
|
|
ASX - By Stock
|
KZA |
Re:
4th GBM CONFERENCE MARCH NEXT
|
|
Gofish1
|
7 |
2.9K |
7 |
15/01/23 |
15/01/23 |
ASX - By Stock
|
7
|
2.9K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Trading Halt
|
|
Gofish1
|
22 |
8.3K |
4 |
13/01/23 |
13/01/23 |
ASX - By Stock
|
22
|
8.3K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Trading Halt
|
|
Gofish1
|
22 |
8.3K |
5 |
12/01/23 |
12/01/23 |
ASX - By Stock
|
22
|
8.3K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
KZA Chart
|
|
Gofish1
|
559 |
156K |
3 |
12/01/23 |
12/01/23 |
ASX - By Stock
|
559
|
156K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: AGM materials
|
|
Gofish1
|
30 |
11K |
0 |
16/11/22 |
16/11/22 |
ASX - By Stock
|
30
|
11K
|
0
|
|
ASX - By Stock
|
KZA |
Re:
Ann: AGM materials
|
|
Gofish1
|
30 |
11K |
2 |
16/11/22 |
16/11/22 |
ASX - By Stock
|
30
|
11K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Gofish1
|
26 |
6.2K |
5 |
31/10/22 |
31/10/22 |
ASX - By Stock
|
26
|
6.2K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Positive melanoma data for Kazia's paxalisib
|
|
Gofish1
|
48 |
14K |
2 |
28/10/22 |
28/10/22 |
ASX - By Stock
|
48
|
14K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Positive melanoma data for Kazia's paxalisib
|
|
Gofish1
|
48 |
14K |
11 |
27/10/22 |
27/10/22 |
ASX - By Stock
|
48
|
14K
|
11
|
|
ASX - By Stock
|
KZA |
Re:
KZA Media Thread
|
|
Gofish1
|
2.0K |
621K |
8 |
15/09/22 |
15/09/22 |
ASX - By Stock
|
2.0K
|
621K
|
8
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Interim data from MSKCC study
|
|
Gofish1
|
47 |
21K |
6 |
24/08/22 |
24/08/22 |
ASX - By Stock
|
47
|
21K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Its a dead duck
|
|
Gofish1
|
69 |
24K |
2 |
18/08/22 |
18/08/22 |
ASX - By Stock
|
69
|
24K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Memorial Sloan Results Imminent
|
|
Gofish1
|
80 |
29K |
5 |
06/08/22 |
06/08/22 |
ASX - By Stock
|
80
|
29K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Gofish1
|
178 |
64K |
0 |
02/08/22 |
02/08/22 |
ASX - By Stock
|
178
|
64K
|
0
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Gofish1
|
178 |
64K |
3 |
02/08/22 |
02/08/22 |
ASX - By Stock
|
178
|
64K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Gofish1
|
178 |
64K |
0 |
02/08/22 |
02/08/22 |
ASX - By Stock
|
178
|
64K
|
0
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Gofish1
|
178 |
64K |
11 |
02/08/22 |
02/08/22 |
ASX - By Stock
|
178
|
64K
|
11
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Gofish1
|
178 |
64K |
1 |
01/08/22 |
01/08/22 |
ASX - By Stock
|
178
|
64K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Gofish1
|
15 |
4.2K |
2 |
29/07/22 |
29/07/22 |
ASX - By Stock
|
15
|
4.2K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Gofish1
|
15 |
4.2K |
6 |
29/07/22 |
29/07/22 |
ASX - By Stock
|
15
|
4.2K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Gofish1
|
15 |
4.2K |
2 |
29/07/22 |
29/07/22 |
ASX - By Stock
|
15
|
4.2K
|
2
|
|
ASX - By Stock
|
SLR |
Re:
Ann: Quarterly Activities Report
|
|
Gofish1
|
14 |
11K |
11 |
27/07/22 |
27/07/22 |
ASX - By Stock
|
14
|
11K
|
11
|
|
ASX - By Stock
|
KZA |
Re:
Memorial Sloan Results Imminent
|
|
Gofish1
|
80 |
29K |
4 |
20/07/22 |
20/07/22 |
ASX - By Stock
|
80
|
29K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia launches new SAB
|
|
Gofish1
|
56 |
15K |
7 |
13/07/22 |
13/07/22 |
ASX - By Stock
|
56
|
15K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
KZA SP / MC Ratio
|
|
Gofish1
|
3 |
1.1K |
1 |
06/07/22 |
06/07/22 |
ASX - By Stock
|
3
|
1.1K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: FDA grants RPDD to paxaliaib for AT/RT
|
|
Gofish1
|
18 |
5.1K |
8 |
06/07/22 |
06/07/22 |
ASX - By Stock
|
18
|
5.1K
|
8
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia progress update
|
|
Gofish1
|
38 |
11K |
3 |
04/07/22 |
04/07/22 |
ASX - By Stock
|
38
|
11K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia progress update
|
|
Gofish1
|
38 |
11K |
7 |
30/06/22 |
30/06/22 |
ASX - By Stock
|
38
|
11K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia progress update
|
|
Gofish1
|
38 |
11K |
4 |
30/06/22 |
30/06/22 |
ASX - By Stock
|
38
|
11K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia progress update
|
|
Gofish1
|
38 |
11K |
11 |
30/06/22 |
30/06/22 |
ASX - By Stock
|
38
|
11K
|
11
|
|
ASX - By Stock
|
KZA |
Re:
KZA Price Performance
|
|
Gofish1
|
11 |
3.5K |
3 |
29/06/22 |
29/06/22 |
ASX - By Stock
|
11
|
3.5K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
KZA Price Performance
|
|
Gofish1
|
11 |
3.5K |
6 |
29/06/22 |
29/06/22 |
ASX - By Stock
|
11
|
3.5K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Change in substantial holding
|
|
Gofish1
|
55 |
13K |
3 |
23/06/22 |
23/06/22 |
ASX - By Stock
|
55
|
13K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia's paxalisib gains ODD for ATRT
|
|
Gofish1
|
9 |
3.1K |
12 |
17/06/22 |
17/06/22 |
ASX - By Stock
|
9
|
3.1K
|
12
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia paxalisib preclinical DIPG data released at IPSNO
|
|
Gofish1
|
12 |
5.1K |
11 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
12
|
5.1K
|
11
|
|
ASX - By Stock
|
KZA |
Re:
KZA Media Thread
|
|
Gofish1
|
2.0K |
621K |
4 |
09/06/22 |
09/06/22 |
ASX - By Stock
|
2.0K
|
621K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
KZA Media Thread
|
|
Gofish1
|
2.0K |
621K |
8 |
09/06/22 |
09/06/22 |
ASX - By Stock
|
2.0K
|
621K
|
8
|
|
ASX - By Stock
|
KZA |
Re:
KZA Media Thread
|
|
Gofish1
|
2.0K |
621K |
7 |
09/06/22 |
09/06/22 |
ASX - By Stock
|
2.0K
|
621K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
News: KZA Kazia Says Phase II Study Of Paxalisib In Brain Metastases Advances To Expansion Stage In...
|
|
Gofish1
|
17 |
5.2K |
1 |
08/06/22 |
08/06/22 |
ASX - By Stock
|
17
|
5.2K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
News: KZA Kazia Says Phase II Study Of Paxalisib In Brain Metastases Advances To Expansion Stage In...
|
|
Gofish1
|
17 |
5.2K |
10 |
08/06/22 |
08/06/22 |
ASX - By Stock
|
17
|
5.2K
|
10
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile opens to paxalisib in Europe
|
|
Gofish1
|
15 |
4.9K |
2 |
02/06/22 |
02/06/22 |
ASX - By Stock
|
15
|
4.9K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
KZA Media Thread
|
|
Gofish1
|
2.0K |
621K |
11 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
2.0K
|
621K
|
11
|
|
ASX - By Stock
|
KZA |
Re:
Latest interview
|
|
Gofish1
|
71 |
22K |
2 |
20/05/22 |
20/05/22 |
ASX - By Stock
|
71
|
22K
|
2
|
|